Loading page…

Report overview

The report presents Kaken's fiscal 2004 performance, with consolidated net sales of ¥74,923 million and net income of ¥3,417 million. It highlights continued investment in regenerative-medicine products based on bFGF alongside endocrine, inflammation, allergy, and infectious-disease development programs. Environmental activities include ISO14001 certification at the Shizuoka production and R&D facilities and a recycling ratio of over 99% for industrial waste.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2004-2005
Period: 1 April 2004 – 31 March 2005
Language
Pages
File size

Standards & Assurance

No standards or assurance data is available for this report.

ESG & Materiality

ESG data

Indicators available in this report:

Employees

No materiality data is available for this report.

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services